argenex SE $ARGX Stock Holdings Increased by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in shares of argenex SE (NASDAQ:ARGX) by 50.1% during the second quarter, HoldingsChannel.com reports. The firm owned 524 shares of the company’s stock after acquiring an additional 175 shares during the period. SG Americas Securities LLC’s holdings in argenex were worth $289,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARGX. WPG Advisers LLC acquired a new stake in shares of argenex during the 1st quarter valued at $37,000. Brooklyn Investment Group raised its holdings in shares of argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 38 shares in the last quarter. Banque Transatlantique SA purchased a new stake in shares of argenex during the first quarter worth $62,000. Geneos Wealth Management Inc. boosted its position in argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in argenex in the first quarter valued at about $76,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Down 0.6%

Shares of argenex stock opened at $911.91 on Friday. The firm has a fifty day simple moving average of $832.19 and a 200-day simple moving average of $694.43. The stock has a market capitalization of $56.15 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 0.92 and a beta of 0.45. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.13.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping the consensus estimate of $4.37 by $0.03. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, research analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Morgan Stanley raised their price target on argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 1st. Citigroup raised their price objective on shares of argenex from $1,041.00 to $1,124.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Finally, Bank of America upped their price objective on shares of argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $903.78.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.